WEBBER, STEPHEN E.,韦伯 斯蒂芬,韋伯 斯蒂芬,ALMASSY, ROBERT J.,艾尔默希 罗伯特,艾爾默希 羅伯特
申请号：
TW106129806
公开号：
TW201823199A
申请日:
2017.08.31
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.For Formula (I) compounds R1, R2, X1, Y1 and n are as defined in the specification. The inventive Formula (I) compounds are inhibitors of the PD-1/PD-L1 protein/protein binding or functional interaction and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer and infectious diseases.本發明提供根據式(I)之化合物或其立體異構物、互變異構物或藥醫上可接受的鹽之合成、醫藥上可接受的調配物和用途。關於式(I)化合物,R1、R2、X1、Y1和n係如說明書中所定義。本發明之式(I)化合物為PD-1/PD-L1蛋白質/蛋白質結合或功能相互作用的抑制劑且發現可於許多的治療應用之效用,包括但不限於治療增殖性疾病諸如癌症和感染性疾病。
